In Depth 13 Nov 2024
Sleep apnea: biotechs snore points in the therapeutic space
Therapeutic strides in biotech are proving to help address different stages of the sleep apnea.
Obesity
- Latest Posts
Sublingual delivery: the future for GLP-1 receptor agonists
Discover how GLP-1 receptor agonists, now thriving in obesity treatment, could benefit from a more patient-friendly sublingual delivery method.
In Depth 25 Sep 2024
How Pfizer’s decision in the ’90s cost them a stronghold in the GLP-1 market
Discover an untold biotech story and find out how Pfizer missed an opportunity in the GLP-1 market because of an exit in the ’90s.
News and Trends 10 Sep 2024
Long non-coding RNAs: what’s behind the growing “dark genome” buzz?
Recent deals have zoned in on drugs that target long non-coding RNAs and major moves are currently being made on the R&D front.
Best in Biotech 5 Sep 2024
Six biotech companies that could revolutionize obesity treatments
In this article, we take a look at six biotechs focused on bringing drugs to treat obesity to the market.
News and Trends 28 Aug 2024
GLP-1 shortage: Can biotech companies keep up with rising demand?
How is the biotech industry responding to the GLP-1 drug shortage? We asked experts in the field to answer this question.
ADVERTISEMENT
ADVERTISEMENT
In Depth 24 Jul 2024
Danuglipron: Is Pfizer’s oral weight loss pill a contender in the obesity market?
Find out more about Pfizer’s GLP-1 candidate danuglipron, as the company aims to compete in the obesity market.
In Depth 25 Mar 2024
Beyond Wegovy: Could Novo Nordisk’s new experimental weight loss pill be even better?
Discover how Novo Nordisk’s new experimental obesity pill, amycretin, could be even more efficient for weight loss than Wegovy.
In Depth 18 Jan 2024
GLP-1 agonists: what’s the hype about?
GLP-1 agonists have been on the radar for a while to treat diabetes and obesity. And of late, there has been renewed interest in these drugs.
In Depth 4 Jan 2024
Can GLP-1 agonists, the miraculous obesity drugs, treat cardiovascular diseases?
Discover how GLP-1 agonists, known for treating diabetes and obesity, are now being studied for their potential in tackling heart diseases.
Best in Biotech 20 Dec 2023
Wrapping up 2023: A recap of top biotech moments of this year
2023 has been an exciting year for the industry. Here are some of the most notable biotech developments in 2023.
Best in Biotech 19 Dec 2023
Nine biotech companies to watch in 2024
2024 is shaping up to be an exciting year for the industry. Discover nine biotech companies to keep an eye on in 2024.
ADVERTISEMENT
